Details of the Drug

General Information of Drug (ID: DMM4JMB)

Drug Name

CTI-1601

Indication

Disease Entry	ICD 11	Status	REF
Friedreich's ataxia	8A03.10	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Recombinant protein

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN ; GCYB1_HUMAN	Stimulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05579691) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's Ataxia. U.S.National Institutes of Health.
2	The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.